Guardant Health (GH) - Company Gross Revenue

High laboratory costs for Guardant Health, Inc. (GH) are offset by the scalability of AI-driven DNA analysis. This chart on GURU.Markets shows the company's sales trajectory reflecting revenue dynamics, where 1.28 characterizes this valuation parameter. Management is currently focusing on the commercial success of its products, aiming to establish "liquid biopsy" as the primary standard for precision oncology diagnostics in clinics.

Guardant360 (GH) Revenue and Sales Volume: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Guardant Health (GH)

- market value and analyst target forecast:

Market Chart Guardant Corp|GH - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Guardant Health, Inc.|GH - Total Company Value

- book capitalization data:

Net Assets per Share Guardant Health|GH - Book Capitalization|Market Value to Equity Ratio guardanthealth.com|GH - Cumulative Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

GH - Company Net Income|Net Profit Forecast Guardant Health, Inc.|GH - Price to Earnings Ratio|Market Cap to Future Earnings Ratio guardanthealth.com|GH - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Guardant Health, Inc.|GH - Operating profit EBITDA|Earnings per share for the trailing year Guardant Health|GH - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months guardanthealth.com|GH - Earnings growth in current year|Earnings growth forecast for next year Guardant Health, Inc.

- company sales and revenue statistics:

GH - Company Revenue|Company Projected Revenue Guardant Corp|GH - Market Cap to Revenue|Price to Expected Revenue Ratio Guardant Health, Inc.

Comprehensive company analysis:Guardant Corp - GH

The growth in commercial revenue for Guardant Health, Inc. (GH) reflects the effectiveness of strategic partnerships with pharmaceutical behemoths in the field of targeted oncology diagnostics. This indicator aggregates daily cash inflows into a continuous trend, allowing investors to assess the real-time expansion of the business in the market and compare scaling rates with the asset's fundamental stability to determine the optimal entry point.

Key competitors